Reduced PRKAB2 expression correlated with poor prognosis and aggressive clinical features, whereas overexpression of PRKAB2 markedly inhibited RCC cell proliferation, migration, invasion, tumor growth, and metastasis both <i>in vitro</i> and <i>in vivo</i>. Here, PRKAB2 is linked to renal cell carcinoma.